Show simple item record

dc.contributor.authorOcan, Moses
dc.contributor.authorAcheng, Frances
dc.contributor.authorOtike, Carol
dc.contributor.authorBeinomugisha, Judith
dc.contributor.authorKatete, David
dc.contributor.authorObua, Celestino
dc.date.accessioned2022-09-09T06:50:29Z
dc.date.available2022-09-09T06:50:29Z
dc.date.issued2022
dc.identifier.citationOcan, M., Acheng, F., Otike, C., Beinomugisha, J., Katete, D., & Obua, C. (2022). Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda. PloS one, 17(1), e0262126.en_US
dc.identifier.urihttp://ir.must.ac.ug/xmlui/handle/123456789/2472
dc.description.abstractHepatitis B vaccine has contributed to the reduction in hepatitis B virus infections and chronic disease globally. Screening to establish extent of vaccine induced immune response and provision of booster dose are limited in most low-and-middle income countries (LMICs). Our study investigated the extent of protective immune response and breakthrough hepatitis B virus infections among adult vaccinated healthcare workers in selected health facilities in northern Uganda. A cross-sectional study was conducted among 300 randomly selected adult hepatitis B vaccinated healthcare workers in Lira and Gulu regional referral hospitals in northern Uganda. Blood samples were collected and qualitative analysis of Hepatitis B surface antigen (HBsAg), Hepatitis B surface antigen antibody (HBsAb), Hepatitis B envelop antigen (HBeAg), Hepatitis B envelop antibody (HBeAb) and Hepatitis B core antibody (HBcAb) conducted using ELISA method. Quantitative assessment of antihepatitis B antibody (anti-HBs) levels was done using COBAS immunoassay analyzer. Mul tiple logistic regression was done to establish factors associated with protective anti-HBs levels (10mIU/mL) among adult vaccinate healthcare workers at 95% level of significance. A high proportion, 81.3% (244/300) of the study participants completed all three hepatitis B vaccine dose schedules. Two (0.7%, 2/300) of the study participants had active hepatitis B virus infection. Of the 300 study participants, 2.3% (7/300) had positive HBsAg; 88.7% (266/ 300) had detectable HBsAb; 2.3% (7/300) had positive HBeAg; 4% (12/300) had positive HBeAb and 17.7% (53/300) had positive HBcAb. Majority, 83% (249/300) had a protective hepatitis B antibody levels (10mIU/mL). Hepatitis B vaccine provides protective immunity against hepatitis B virus infection regardless of whether one gets a booster dose or not. Protective immune response persisted for over ten years following hepatitis B vaccination among the healthcare workersen_US
dc.description.sponsorshipFogarty International Center of the National Institutes of Health, U.S. Department of State’s Office of the U.S Global AIDS Coordinator and Health Diplomacy (S/GAC), and President’s Emergency Plan for AIDS (PEPFAR) under Award Number IR25TW011213en_US
dc.language.isoen_USen_US
dc.publisherPloS oneen_US
dc.subjectHepatitis Ben_US
dc.subjectScreeningen_US
dc.subjectVaccinationen_US
dc.subjectUgandaen_US
dc.titleAntibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Ugandaen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record